Reprogramming the tumor microenvironment leverages CD8+ T cell responses to a shared tumor/self antigen in ovarian cancer

Vesely, 2011, Natural innate and adaptive immunity to cancer, Annu. Rev. Immunol., 29, 235, 10.1146/annurev-immunol-031210-101324 Schietinger, 2014, Tolerance and exhaustion: defining mechanisms of T cell dysfunction, Trends Immunol., 35, 51, 10.1016/j.it.2013.10.001 Nelson, 2019, Reprogramming responsiveness to checkpoint blockade in dysfunctional CD8 T cells, Proc. Natl. Acad. Sci. USA, 116, 2640, 10.1073/pnas.1810326116 Nelson, 2019, Robust iterative stimulation with self-antigens overcomes CD8(+) T cell tolerance to self- and tumor antigens, Cell Rep., 28, 3092, 10.1016/j.celrep.2019.08.038 Rosato, 2019, Virus-specific memory T cells populate tumors and can be repurposed for tumor immunotherapy, Nat. Commun., 10, 567, 10.1038/s41467-019-08534-1 van Vloten, 2018, Critical interactions between immunogenic cancer cell death, oncolytic viruses, and the immune System define the rational design of combination immunotherapies, J. Immunol., 200, 450, 10.4049/jimmunol.1701021 Guo, 2019, Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics, J. Immunother. Cancer, 7, 6, 10.1186/s40425-018-0495-7 Ribas, 2018, Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy, Cell, 174, 1031, 10.1016/j.cell.2018.07.035 Gil, 2013, Targeting CXCL12/CXCR4 signaling with oncolytic virotherapy disrupts tumor vasculature and inhibits breast cancer metastases, Proc. Natl. Acad. Sci. USA, 110, E1291, 10.1073/pnas.1220580110 Gil, 2014, CXCL12/CXCR4 blockade by oncolytic virotherapy inhibits ovarian cancer growth by decreasing immunosuppression and targeting cancer-initiating cells, J. Immunol., 193, 5327, 10.4049/jimmunol.1400201 Komorowski, 2016, Reprogramming antitumor immunity against chemoresistant ovarian cancer by a CXCR4 antagonist-armed viral oncotherapy, Mol. Ther. Oncolytics, 3, 16034, 10.1038/mto.2016.34 Mistarz, 2019, Recruitment of intratumoral CD103(+) dendritic cells by a CXCR4 antagonist-armed virotherapy enhances antitumor immunity, Mol. Ther. Oncolytics, 14, 233, 10.1016/j.omto.2019.06.003 Kryczek, 2005, CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers, Cancer Res., 65, 465, 10.1158/0008-5472.465.65.2 Fearon, 2014, The carcinoma-associated fibroblast expressing fibroblast activation protein and escape from immune surveillance, Cancer Immunol. Res., 2, 187, 10.1158/2326-6066.CIR-14-0002 Orimo, 2005, Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion, Cell, 121, 335, 10.1016/j.cell.2005.02.034 Obermajer, 2011, PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment, Cancer Res., 71, 7463, 10.1158/0008-5472.CAN-11-2449 Curiel, 2004, Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival, Nat. Med., 10, 942, 10.1038/nm1093 Chen, 2019 Huang, 2009, A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer, J. Surg. Res., 155, 231, 10.1016/j.jss.2008.06.044 Devine, 2004, Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma, J. Clin. Oncol., 22, 1095, 10.1200/JCO.2004.07.131 Wong, 2008, Translating an antagonist of chemokine receptor CXCR4: from bench to bedside, Clin. Cancer Res., 14, 7975, 10.1158/1078-0432.CCR-07-4846 Quinn, 2010, Development of a syngeneic mouse model of epithelial ovarian cancer, J. Ovarian Res., 3, 24, 10.1186/1757-2215-3-24 Connolly, 2009, Xenograft and transgenic mouse models of epithelial ovarian cancer and non invasive imaging modalities to monitor ovarian tumor growth in situ -applications in evaluating novel therapeutic agents, Curr. Protoc. Pharmacol., 45, 14.12.1, 10.1002/0471141755.ph1412s45 Wang, 2019, “Acquired” NKG2D ligand stimulates NK cell-mediated tumor immunosurveillance, J. Immunother., 42, 189, 10.1097/CJI.0000000000000276 Yuan, 2017, Prognostic significance of tumor-associated macrophages in ovarian cancer: a meta-analysis, Gynecol. Oncol., 147, 181, 10.1016/j.ygyno.2017.07.007 Wang, 2011, Transition of tumor-associated macrophages from MHC class II(hi) to MHC class II(low) mediates tumor progression in mice, BMC Immunol., 12, 43, 10.1186/1471-2172-12-43 Hussain, 2020, Distinct fibroblast functional states drive clinical outcomes in ovarian cancer and are regulated by TCF21, J. Exp. Med., 217, e20191094, 10.1084/jem.20191094 Comito, 2014, Cancer-associated fibroblasts and M2-polarized macrophages synergize during prostate carcinoma progression, Oncogene, 33, 2423, 10.1038/onc.2013.191 Cremasco, 2018, FAP delineates heterogeneous and functionally divergent stromal cells in immune-excluded breast tumors, Cancer Immunol. Res., 6, 1472, 10.1158/2326-6066.CIR-18-0098 Ilkow, 2015, Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity, Nat. Med., 21, 530, 10.1038/nm.3848 Everts, 2020, Simultaneous tumor and stroma targeting by oncolytic viruses, Biomedicines, 8, 474, 10.3390/biomedicines8110474 Wang, 2022, Remodeling the tumor microenvironment by oncolytic viruses: beyond oncolysis of tumor cells for cancer treatment, J. Immunother. Cancer, 10, e004167, 10.1136/jitc-2021-004167 Righi, 2011, CXCL12/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancer, Cancer Res., 71, 5522, 10.1158/0008-5472.CAN-10-3143 Burrack, 2015, Myeloid cell Arg1 inhibits control of arthritogenic alphavirus infection by suppressing antiviral T cells, PLoS Pathog., 11, e1005191, 10.1371/journal.ppat.1005191 Jablonski, 2015, Novel markers to delineate murine M1 and M2 macrophages, PLoS One, 10, e0145342, 10.1371/journal.pone.0145342 Yang, 2014, Functions of arginase isoforms in macrophage inflammatory responses: impact on cardiovascular diseases and metabolic disorders, Front. Immunol., 5, 533, 10.3389/fimmu.2014.00533 Yu, 2019, Modulation of M2 macrophage polarization by the crosstalk between Stat6 and Trim24, Nat. Commun., 10, 4353, 10.1038/s41467-019-12384-2 Conde, 2015, DC-SIGN(+) macrophages control the induction of transplantation tolerance, Immunity, 42, 1143, 10.1016/j.immuni.2015.05.009 Psallidas, 2013, Secreted phosphoprotein-1 directly provokes vascular leakage to foster malignant pleural effusion, Oncogene, 32, 528, 10.1038/onc.2012.57 Wei, 2020, The significance of secreted phosphoprotein 1 in multiple human cancers, Front. Mol. Biosci., 7, 565383, 10.3389/fmolb.2020.565383 Kwak, 2020, Distinct populations of immune-suppressive macrophages differentiate from monocytic myeloid-derived suppressor cells in cancer, Cell Rep., 33, 108571, 10.1016/j.celrep.2020.108571 Sharma, 2021, LILRB4 suppresses immunity in solid tumors and is a potential target for immunotherapy, J. Exp. Med., 218, e20201811, 10.1084/jem.20201811 Lee, 2022, A novel cytokine consisting of the p40 and EBI3 subunits suppresses experimental autoimmune arthritis via reciprocal regulation of Th17 and Treg cells, Cell. Mol. Immunol., 19, 79, 10.1038/s41423-021-00798-2 Grauel, 2020, TGFbeta-blockade uncovers stromal plasticity in tumors by revealing the existence of a subset of interferon-licensed fibroblasts, Nat. Commun., 11, 6315, 10.1038/s41467-020-19920-5 Wang, 2017, Increased expression of S100A6 promotes cell proliferation in gastric cancer cells, Oncol. Lett., 13, 222, 10.3892/ol.2016.5419 Nedjadi, 2009, S100A6 binds to annexin 2 in pancreatic cancer cells and promotes pancreatic cancer cell motility, Br. J. Cancer, 101, 1145, 10.1038/sj.bjc.6605289 Teeuwssen, 2019, Wnt signaling in ovarian cancer stemness, EMT, and therapy resistance, J. Clin. Med., 8, 1658, 10.3390/jcm8101658 Weisz, 2004, Transactivation of the EGR1 gene contributes to mutant p53 gain of function, Cancer Res., 64, 8318, 10.1158/0008-5472.CAN-04-1145 Schietinger, 2016, Tumor-specific T cell dysfunction is a dynamic antigen-driven differentiation program initiated early during tumorigenesis, Immunity, 45, 389, 10.1016/j.immuni.2016.07.011 Chen, 2019, TCF-1-Centered transcriptional network drives an effector versus exhausted CD8 T cell-fate decision, Immunity, 51, 840, 10.1016/j.immuni.2019.09.013 Chu, 2020, Two parallel worlds of memory T cells, Nat. Immunol., 21, 1484, 10.1038/s41590-020-00815-y Siddiqui, 2019, Intratumoral tcf1(+)PD-1(+)CD8(+) T cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy, Immunity, 50, 195, 10.1016/j.immuni.2018.12.021 Wu, 2016, The TCF1-Bcl6 axis counteracts type I interferon to repress exhaustion and maintain T cell stemness, Sci. Immunol., 1, eaai8593, 10.1126/sciimmunol.aai8593 Westgaard, 2003, The lectin-like receptor KLRE1 inhibits natural killer cell cytotoxicity, J. Exp. Med., 197, 1551, 10.1084/jem.20021253 Philip, 2017, Chromatin states define tumour-specific T cell dysfunction and reprogramming, Nature, 545, 452, 10.1038/nature22367 Jiang, 2020, Exhausted CD8+T cells in the tumor immune microenvironment: new pathways to therapy, Front. Immunol., 11, 622509, 10.3389/fimmu.2020.622509 Schietinger, 2012, Rescued tolerant CD8 T cells are preprogrammed to reestablish the tolerant state, Science, 335, 723, 10.1126/science.1214277 Enouz, 2012, Autoreactive T cells bypass negative selection and respond to self-antigen stimulation during infection, J. Exp. Med., 209, 1769, 10.1084/jem.20120905 Kalluri, 2016, The biology and function of fibroblasts in cancer, Nat. Rev. Cancer, 16, 582, 10.1038/nrc.2016.73 Dominguez, 2020, Single-cell RNA sequencing reveals stromal evolution into LRRC15(+) myofibroblasts as a determinant of patient response to cancer immunotherapy, Cancer Discov., 10, 232, 10.1158/2159-8290.CD-19-0644 Pan, 2020, Tumor-associated macrophages in tumor immunity, Front. Immunol., 11, 583084, 10.3389/fimmu.2020.583084 Freedman, 2018, An oncolytic virus expressing a T-cell engager simultaneously targets cancer and immunosuppressive stromal cells, Cancer Res., 78, 6852, 10.1158/0008-5472.CAN-18-1750 Zhu, 2021, Efficacy of PD-1/PD-L1 inhibitors in ovarian cancer: a single-arm meta-analysis, J. Ovarian Res., 14, 112, 10.1186/s13048-021-00862-5 Drakes, 2020, Immune checkpoint blockade in gynecologic cancers: state of affairs, Cancers (Basel), 12, 10.3390/cancers12113301 Lal, 2021, Comparing syngeneic and autochthonous models of breast cancer to identify tumor immune components that correlate with response to immunotherapy in breast cancer, Breast Cancer Res., 23, 83, 10.1186/s13058-021-01448-1 Hashiguchi, 2001, Combined analysis of p53 and RB pathways in epithelial ovarian cancer, Hum. Pathol., 32, 988, 10.1053/hupa.2001.27115 Arroyo, 2005, Involvement of PP2A in viral and cellular transformation, Oncogene, 24, 7746, 10.1038/sj.onc.1209038 Altomare, 2004, AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth, Oncogene, 23, 5853, 10.1038/sj.onc.1207721 Cell Ranger Single-Cell Software Suite (2020). http://software.10xgenomics.com/single-cell/overview/welcome. Satija, 2015, Spatial reconstruction of single-cell gene expression data, Nat. Biotechnol., 33, 495, 10.1038/nbt.3192 Aran, 2019, Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage, Nat. Immunol., 20, 163, 10.1038/s41590-018-0276-y Korotkevich, 2019 Blighe, 2021 Pheatmap R package (2019). https://cran.r-project.org/package=pheatmap. Aibar, 2017, SCENIC: single-cell regulatory network inference and clustering, Nat. Methods, 14, 1083, 10.1038/nmeth.4463 Liberzon, 2011, Molecular signatures database (MSigDB) 3.0, Bioinformatics, 27, 1739, 10.1093/bioinformatics/btr260